Introduction
At least 60% of patients with Hodgkin's disease [1] and around 20% of patients with NHL have mediastinal involvement [2] , which is associated with a high risk for relapse when the mass is bulky. That is the reason for submitting them for additional radiotherapy, but mediastinal abnormalities are present in as many as 50% of patients with mediastinal involvement following the completion of therapy [3] . These are potential sites for lymphoma persistence and recurrence. The same problem has to be solved in other locations with residual mass. In cases of remaining tumor tissue, it could be useful to intensify chemotherapy immediately, for instance, by peripheral stem-cell transplantation, instead of following the usual watch-and-wait policy.
Positron emission tomography (PET) with 2-[F-18]-fluoro-2-deoxy-D-glucose (FDG) has shown increasing promise in oncologic imaging [4] , FDG uptake has been shown in a variety of malignant neoplasms including lymphomas [5] [6] [7] [8] . Vital tumor cells accumulate FDG depending on the tracer transport and the hexokinase activity of the cells, because the activity of glucose-6-phosphatase is low [9] and FDG is metabolically trapped as 18F-2-deoxy-D-glucose-phosphate after phosphorylation by hexokinase [10] . Tumors generally have a continuous influx of FDG over time while normal tissues generally show tracer efflux [11] . Therefore, FDG-PET may offer the possibility of differentiating sites of vital tumor from necrotic residual masses.
Patients and methods
After therapy, 34 patients with suspected residual disease underwent FDG-PET after completion of chemotherapy or chemotherapy and radiotherapy. Seventeen patients suffered from Hodgkin's disease and 17 patients from non-Hodgkin's lymphoma (NHL) (subtypes in Table 1 ). Median age was 43 (21-73) years. At diagnosis, 7 patients presented with stage I, 13 with stage II, 5 with stage III, and 9 with stage IV (Table 2) . Extranodal lesions were present in 11 patients additional to the patients in stage IV. Six of them showed stage IE, 5 stage HE. The localizations are shown in Table 3 . Routine staging methods included clinical examination, laboratory screening, chest X-ray, computed tomography of thorax and abdomen, ultrasound, bone biopsy, and if indicated, liver biopsy and magnetic resonance imaging (MRI) in patients with bone or soft tissue involvement.
At a median time of 6 weeks (range 2-40 weeks) after completion of therapy during fasting state for at least 6 hours, whole-body FDG-PET was performed 30-60 minutes after i.v. bolus injection of 250-400 Mbq FDG using a Siemens ECAT exact 47 PET-scanner with a view field of 16.2 cm. Brain was included in one patient with primary cerebral NHL. The other examinations excluded brain and lower extremities. Usually 4 to 5 bed positions were necessary for a whole-body PET. To keep the time in the scanner for the patients short, no attenuation correction was performed. After filtered back projection, the scan was evaluated visually during daily routine.
Results
According to routine radiological staging, 2 patients achieved CR, while residual mass was found in 32 pa- tients. Mediastinal widening was persistent in many patients and the most frequent site of residual mass. In extranodal manifestations, residual mass was observed frequently ( Table 4 ). The diameter of the mass ranged from 0.6 cm to 7 cm in the group with FDG uptake as well as in the group without FDG accumulation. Median follow-up is 52 weeks (range 4-102 weeks).
Complete response with PET
One of the patients in CR had no FDG accumulation in PET. He was considered to be in CR. Overall, FDG-PET was negative in 17 patients. All these patients were considered to be in CR. None of them relapsed after a median follow-up of 62.6 weeks (range 4-102 weeks). One patient died of pulmonary embolism 41 weeks after PET without relapse.
FDG accumulation with PET
FDG-PET was positive in 17 patients, of whom 16 had a residual mass with routine radiological methods.
Positive PET after chemotherapy prior to radiotherapy. Four patients received radiotherapy after PET and did not get another PET after radiotherapy. So the final FDG uptake after completed therapy is not known. The average follow-up is 58 weeks (26-84 weeks) without relapse for these patients.
FDG uptake in the residual mass. Ten patients showed FDG accumulation in the residual mass. In 5 patients this result was histologically confirmed, in 3 patients at once, and in 2 more patients at time of relapse according to routine methods. Two additional patients relapsed 40 and 6 weeks after PET. Pathological staging was not performed. Overall, 7 of 10 patients with FDG uptake in the residual mass relapsed. The remaining 3 patients have a follow-up of 6, 14, and 39 weeks. The patient with the longest follow-up is likely to be false positive because of a fracture in the humerus at the lymphoma site.
FDG uptake outside the residual mass. Three patients showed FDG uptake outside the residual mass only. One patient showed nodular pleural uptake of unknown origin. The second patient accumulated FDG in the right lower lobe of the lung, but did not accumulate FDG in the suspicious cervical lymph node. Bronchoscopy with bronchial lavage and microbiological culture revealed pneumonia caused by Haemophilus influencae. One patient had reached CR according to routine radiological staging. FDG-PET was the first method to show an additional focus in the left humerus without clinical symptoms. The focus was confirmed by MRI but not by bone scintigraphy. The patient refused histological staining, but three months later progressive disease could be shown and biopsy revealed Hodgkin's disease.
Overall, after completed therapy, there have been no false-negative results, two false-positive results outside, and three false-positive results inside the residual mass. Sensitivity, positive, and overall predictive value for dignity of residual mass show a trend in favor of PET in comparison to CT as shown in Table 5 . In particular, specificity (73% vs. 3.9%) and negative predictive value (50% vs. 100%) are higher with PET.
Discussion
Imaging techniques have improved in the ability to identify morphological alterations with the introduction of high resolution computed tomography and magnetic resonance imaging. Unfortunately, it is even more difficult to judge the significance of the findings under certain circumstances.
While thoracic and abdominal CT are used as routine staging methods and it is widely accepted that lymphangiography has no place in the management of lymphoma [12] , other techniques are still a point of discussion. For staging of cervical lymph nodes, ultrasound examination seems to be of value [13] . In a comparison of initial lymphoma staging using CT and MR imaging, MR detected all lesions found by CT, but only MR detected marrow involvement [14] . Various monoclonal antibodies and Fab fragments of monoclonal antibodies labeled with iodine 131 or indium 111 have been investigated for radioimmunodetection of lymphomas [15] [16] [17] . There are some promising results [18] but generally, disadvantages are the late examination after injection, next splenic targeting is usually demonstrated, and sensitivity is relatively low. The results for somatostatin receptor scintigraphy have not been uniformly predictive for lymphoma involvement, and routine use is not recommended [19}.
There have been many different studies to define the value of gallium-67 scanning as a transferrin receptor agent in staging lymphomas, especially after therapy with residual mass [20, 21] . Anderson et al. found an overall predictive value of 96% and a specificity of 90% or greater for both Hodgkin's disease and non-Hodgkin's lymphoma for gallium-67 scanning [22] . In a comparison of MRI and gallium-67 scintigraphy, MRI showed more inconclusive signals (15%) [23] . To diagnose relapse in Hodgkin's disease with residual mass as early as possible, a lot of methods have been evaluated, including erythrocyte sedimentation rate (ESR), MRI, and gallium scintigraphy [24] . Even for MRI, the sensitivity was only 45% which is obviously too low for practical needs. Gallium-67 scanning is considered to be the standard in judging the residual mass and has been compared with many methods [25] [26] [27] .
In the mediastinum, residual masses are generally defined as a mass greater than 2 cm observed on the CT scan. In our analysis, patients with a residual mass smaller than 1 cm at different sites were included and showed suspicious FDG uptake. These were sites of relapse with histologically confirmed lymphoma. These findings demonstrate that lesions smaller than 1 cm can be judged with PET. PET offers potential advantages over gallium-67 scintigraphy, particularly in the abdomen, as interpretation of PET normally is unimpeded by massive bowel excretion of radionuclides. Moreover, imaging is possible within one hour of FDG injection, unlike gallium-67, which requires long delays from injection until imaging. Furthermore, the radiation exposure overall is less using FDG.
In investigational PET, the standard evaluation included at least semiquantitative evaluation as standard uptake values or differential uptake values [28] . The FDG uptake in the region of interest is compared with normal tissue. Many publications [29] [30] [31] demonstrate the equivalence of visual analysis of experienced specialists and the semiquantitative evaluation. Therefore, in this study only visual analysis was performed and shows conclusive results.
The main finding in this study was that FDG-PET was highly specific for detecting recurrent lymphoma in patients with residual mass. There was also a trend for FDG-PET to be more sensitive as well as more specific than CT. The main disadvantage of this study is the short follow-up.
For those cases in which a CTscan is nonconclusive in terms of disease activity, we believe that FDG-PET is the most helpful noninvasive modality in differentiating recurrence or residual disease from fibrosis. FDG-PET should play a crucial role when CT depicts a residual mass indistinguishable from active disease, especially in cases where further therapeutic steps are to be taken in the management of patients.
